S&P 500   3,844.84 (+0.08%)
DOW   31,928.64 (+1.37%)
QQQ   304.04 (-1.50%)
AAPL   117.57 (-3.17%)
MSFT   229.81 (-0.77%)
FB   259.06 (-1.98%)
GOOGL   2,038.48 (-2.79%)
TSLA   575.69 (-3.72%)
AMZN   2,997.98 (-0.08%)
NVDA   471.00 (-5.51%)
BABA   228.03 (-2.51%)
CGC   31.39 (+0.71%)
GE   14.18 (+4.26%)
MU   86.32 (-2.93%)
NIO   35.97 (-5.62%)
AMD   75.59 (-3.73%)
T   30.36 (+2.50%)
F   12.66 (+3.18%)
ACB   9.72 (+1.25%)
DIS   200.18 (+5.36%)
BA   226.80 (+1.60%)
NFLX   502.86 (-2.62%)
PFE   34.63 (+0.70%)
S&P 500   3,844.84 (+0.08%)
DOW   31,928.64 (+1.37%)
QQQ   304.04 (-1.50%)
AAPL   117.57 (-3.17%)
MSFT   229.81 (-0.77%)
FB   259.06 (-1.98%)
GOOGL   2,038.48 (-2.79%)
TSLA   575.69 (-3.72%)
AMZN   2,997.98 (-0.08%)
NVDA   471.00 (-5.51%)
BABA   228.03 (-2.51%)
CGC   31.39 (+0.71%)
GE   14.18 (+4.26%)
MU   86.32 (-2.93%)
NIO   35.97 (-5.62%)
AMD   75.59 (-3.73%)
T   30.36 (+2.50%)
F   12.66 (+3.18%)
ACB   9.72 (+1.25%)
DIS   200.18 (+5.36%)
BA   226.80 (+1.60%)
NFLX   502.86 (-2.62%)
PFE   34.63 (+0.70%)
S&P 500   3,844.84 (+0.08%)
DOW   31,928.64 (+1.37%)
QQQ   304.04 (-1.50%)
AAPL   117.57 (-3.17%)
MSFT   229.81 (-0.77%)
FB   259.06 (-1.98%)
GOOGL   2,038.48 (-2.79%)
TSLA   575.69 (-3.72%)
AMZN   2,997.98 (-0.08%)
NVDA   471.00 (-5.51%)
BABA   228.03 (-2.51%)
CGC   31.39 (+0.71%)
GE   14.18 (+4.26%)
MU   86.32 (-2.93%)
NIO   35.97 (-5.62%)
AMD   75.59 (-3.73%)
T   30.36 (+2.50%)
F   12.66 (+3.18%)
ACB   9.72 (+1.25%)
DIS   200.18 (+5.36%)
BA   226.80 (+1.60%)
NFLX   502.86 (-2.62%)
PFE   34.63 (+0.70%)
S&P 500   3,844.84 (+0.08%)
DOW   31,928.64 (+1.37%)
QQQ   304.04 (-1.50%)
AAPL   117.57 (-3.17%)
MSFT   229.81 (-0.77%)
FB   259.06 (-1.98%)
GOOGL   2,038.48 (-2.79%)
TSLA   575.69 (-3.72%)
AMZN   2,997.98 (-0.08%)
NVDA   471.00 (-5.51%)
BABA   228.03 (-2.51%)
CGC   31.39 (+0.71%)
GE   14.18 (+4.26%)
MU   86.32 (-2.93%)
NIO   35.97 (-5.62%)
AMD   75.59 (-3.73%)
T   30.36 (+2.50%)
F   12.66 (+3.18%)
ACB   9.72 (+1.25%)
DIS   200.18 (+5.36%)
BA   226.80 (+1.60%)
NFLX   502.86 (-2.62%)
PFE   34.63 (+0.70%)
Log in
NASDAQ:GBT

Global Blood Therapeutics Competitors

$39.64
-1.32 (-3.22 %)
(As of 03/8/2021 02:38 PM ET)
Add
Compare
Today's Range
$39.45
Now: $39.64
$41.22
50-Day Range
$40.34
MA: $48.15
$50.85
52-Week Range
$36.49
Now: $39.64
$83.69
Volume52,478 shs
Average Volume1.08 million shs
Market Capitalization$2.46 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.39

Competitors

Global Blood Therapeutics (NASDAQ:GBT) Vs. MRTX, JAZZ, BBIO, RARE, ASND, and ACAD

Should you be buying GBT stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Global Blood Therapeutics, including Mirati Therapeutics (MRTX), Jazz Pharmaceuticals (JAZZ), BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE), Ascendis Pharma A/S (ASND), and ACADIA Pharmaceuticals (ACAD).

Global Blood Therapeutics (NASDAQ:GBT) and Mirati Therapeutics (NASDAQ:MRTX) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares Global Blood Therapeutics and Mirati Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Global Blood Therapeutics-332.94%-56.43%-39.32%
Mirati TherapeuticsN/A-60.01%-54.21%

Valuation and Earnings

This table compares Global Blood Therapeutics and Mirati Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Global Blood Therapeutics$2.11 million1,167.73$-266,770,000.00($4.71)-8.42
Mirati Therapeutics$3.34 million2,907.51$-213,260,000.00($5.69)-33.71

Mirati Therapeutics has higher revenue and earnings than Global Blood Therapeutics. Mirati Therapeutics is trading at a lower price-to-earnings ratio than Global Blood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

94.9% of Mirati Therapeutics shares are owned by institutional investors. 4.3% of Global Blood Therapeutics shares are owned by company insiders. Comparatively, 4.1% of Mirati Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Global Blood Therapeutics and Mirati Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Global Blood Therapeutics051202.71
Mirati Therapeutics151002.56

Global Blood Therapeutics currently has a consensus price target of $93.8235, suggesting a potential upside of 133.68%. Mirati Therapeutics has a consensus price target of $218.5714, suggesting a potential upside of 13.20%. Given Global Blood Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Global Blood Therapeutics is more favorable than Mirati Therapeutics.

Risk and Volatility

Global Blood Therapeutics has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, Mirati Therapeutics has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500.

Summary

Global Blood Therapeutics beats Mirati Therapeutics on 8 of the 14 factors compared between the two stocks.

Global Blood Therapeutics (NASDAQ:GBT) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares Global Blood Therapeutics and Jazz Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Global Blood Therapeutics-332.94%-56.43%-39.32%
Jazz Pharmaceuticals7.86%20.16%10.85%

Valuation and Earnings

This table compares Global Blood Therapeutics and Jazz Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Global Blood Therapeutics$2.11 million1,167.73$-266,770,000.00($4.71)-8.42
Jazz Pharmaceuticals$2.16 billion4.25$523.37 million$14.6011.17

Jazz Pharmaceuticals has higher revenue and earnings than Global Blood Therapeutics. Global Blood Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

95.7% of Jazz Pharmaceuticals shares are owned by institutional investors. 4.3% of Global Blood Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Jazz Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Global Blood Therapeutics and Jazz Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Global Blood Therapeutics051202.71
Jazz Pharmaceuticals111602.83

Global Blood Therapeutics currently has a consensus price target of $93.8235, suggesting a potential upside of 133.68%. Jazz Pharmaceuticals has a consensus price target of $184.00, suggesting a potential upside of 11.38%. Given Global Blood Therapeutics' higher probable upside, research analysts plainly believe Global Blood Therapeutics is more favorable than Jazz Pharmaceuticals.

Risk and Volatility

Global Blood Therapeutics has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Summary

Jazz Pharmaceuticals beats Global Blood Therapeutics on 11 of the 14 factors compared between the two stocks.

Global Blood Therapeutics (NASDAQ:GBT) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares Global Blood Therapeutics and BridgeBio Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Global Blood Therapeutics-332.94%-56.43%-39.32%
BridgeBio PharmaN/A-109.88%-48.54%

Valuation and Earnings

This table compares Global Blood Therapeutics and BridgeBio Pharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Global Blood Therapeutics$2.11 million1,167.73$-266,770,000.00($4.71)-8.42
BridgeBio Pharma$40.56 million220.83$-260,590,000.00($2.48)-24.25

BridgeBio Pharma has higher revenue and earnings than Global Blood Therapeutics. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Global Blood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

95.5% of BridgeBio Pharma shares are owned by institutional investors. 4.3% of Global Blood Therapeutics shares are owned by company insiders. Comparatively, 40.3% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Global Blood Therapeutics and BridgeBio Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Global Blood Therapeutics051202.71
BridgeBio Pharma01802.89

Global Blood Therapeutics currently has a consensus price target of $93.8235, suggesting a potential upside of 133.68%. BridgeBio Pharma has a consensus price target of $67.25, suggesting a potential upside of 9.65%. Given Global Blood Therapeutics' higher probable upside, research analysts plainly believe Global Blood Therapeutics is more favorable than BridgeBio Pharma.

Risk and Volatility

Global Blood Therapeutics has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Global Blood Therapeutics (NASDAQ:GBT) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Global Blood Therapeutics and Ultragenyx Pharmaceutical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Global Blood Therapeutics051202.71
Ultragenyx Pharmaceutical06802.57

Global Blood Therapeutics currently has a consensus price target of $93.8235, suggesting a potential upside of 133.68%. Ultragenyx Pharmaceutical has a consensus price target of $131.20, suggesting a potential upside of 11.56%. Given Global Blood Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Global Blood Therapeutics is more favorable than Ultragenyx Pharmaceutical.

Valuation and Earnings

This table compares Global Blood Therapeutics and Ultragenyx Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Global Blood Therapeutics$2.11 million1,167.73$-266,770,000.00($4.71)-8.42
Ultragenyx Pharmaceutical$103.71 million75.74$-402,730,000.00($7.36)-15.94

Global Blood Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Global Blood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Global Blood Therapeutics has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500.

Profitability

This table compares Global Blood Therapeutics and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Global Blood Therapeutics-332.94%-56.43%-39.32%
Ultragenyx Pharmaceutical-119.19%-50.69%-26.87%

Summary

Global Blood Therapeutics beats Ultragenyx Pharmaceutical on 7 of the 12 factors compared between the two stocks.

Ascendis Pharma A/S (NASDAQ:ASND) and Global Blood Therapeutics (NASDAQ:GBT) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Ascendis Pharma A/S and Global Blood Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ascendis Pharma A/S001303.00
Global Blood Therapeutics051202.71

Ascendis Pharma A/S presently has a consensus target price of $183.00, suggesting a potential upside of 26.98%. Global Blood Therapeutics has a consensus target price of $93.8235, suggesting a potential upside of 133.68%. Given Global Blood Therapeutics' higher probable upside, analysts clearly believe Global Blood Therapeutics is more favorable than Ascendis Pharma A/S.

Earnings and Valuation

This table compares Ascendis Pharma A/S and Global Blood Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascendis Pharma A/S$14.98 million510.77$-244,180,000.00($5.25)-27.28
Global Blood Therapeutics$2.11 million1,167.73$-266,770,000.00($4.71)-8.42

Ascendis Pharma A/S has higher revenue and earnings than Global Blood Therapeutics. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Global Blood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Ascendis Pharma A/S has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Global Blood Therapeutics has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500.

Profitability

This table compares Ascendis Pharma A/S and Global Blood Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ascendis Pharma A/S-4,042.79%-55.72%-49.42%
Global Blood Therapeutics-332.94%-56.43%-39.32%

Summary

Global Blood Therapeutics beats Ascendis Pharma A/S on 7 of the 12 factors compared between the two stocks.

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Global Blood Therapeutics (NASDAQ:GBT) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for ACADIA Pharmaceuticals and Global Blood Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ACADIA Pharmaceuticals011213.00
Global Blood Therapeutics051202.71

ACADIA Pharmaceuticals presently has a consensus target price of $62.00, suggesting a potential upside of 29.09%. Global Blood Therapeutics has a consensus target price of $93.8235, suggesting a potential upside of 133.68%. Given Global Blood Therapeutics' higher probable upside, analysts clearly believe Global Blood Therapeutics is more favorable than ACADIA Pharmaceuticals.

Insider & Institutional Ownership

93.5% of ACADIA Pharmaceuticals shares are owned by institutional investors. 27.7% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 4.3% of Global Blood Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares ACADIA Pharmaceuticals and Global Blood Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ACADIA Pharmaceuticals$339.08 million22.19$-235,260,000.00($1.60)-29.39
Global Blood Therapeutics$2.11 million1,167.73$-266,770,000.00($4.71)-8.42

ACADIA Pharmaceuticals has higher revenue and earnings than Global Blood Therapeutics. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Global Blood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

ACADIA Pharmaceuticals has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Global Blood Therapeutics has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.

Profitability

This table compares ACADIA Pharmaceuticals and Global Blood Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ACADIA Pharmaceuticals-63.92%-40.35%-34.72%
Global Blood Therapeutics-332.94%-56.43%-39.32%

Summary

ACADIA Pharmaceuticals beats Global Blood Therapeutics on 11 of the 14 factors compared between the two stocks.


Global Blood Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$191.79-0.6%$9.65 billion$3.34 million-24.91Analyst Report
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$163.13-1.0%$9.28 billion$2.16 billion51.46Analyst Report
Increase in Short Interest
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
1.6$60.13-3.5%$9.27 billion$40.56 million-17.63
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.4$117.33-1.0%$7.93 billion$103.71 million-26.73
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$143.24-2.6%$7.85 billion$14.98 million-17.45Upcoming Earnings
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.8$47.02-4.2%$7.84 billion$339.08 million-27.34Analyst Revision
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.4$51.99-1.5%$7.43 billion$1.12 billion108.31
United Therapeutics logo
UTHR
United Therapeutics
1.9$160.80-2.2%$7.32 billion$1.45 billion15.21Analyst Revision
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$66.48-3.8%$7.16 billion$87.99 million-79.14
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$84.15-0.8%$6.69 billion$380.83 million-10.76Earnings Announcement
Analyst Report
Analyst Revision
Gap Up
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$215.01-0.0%$6.67 billion$311.33 million-125.01
Allakos logo
ALLK
Allakos
1.7$123.24-0.4%$6.57 billionN/A-44.98Insider Selling
Analyst Revision
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.9$35.62-0.1%$6.00 billionN/A0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$42.69-1.4%$5.69 billion$150,000.00-20.14Earnings Announcement
Analyst Revision
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$92.40-3.8%$5.56 billion$66.51 million17.05
Galapagos logo
GLPG
Galapagos
1.3$82.05-2.0%$5.47 billion$1.00 billion-12.43
Perrigo logo
PRGO
Perrigo
2.4$42.36-3.1%$5.46 billion$4.84 billion-705.88Analyst Report
Analyst Revision
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.9$109.09-2.6%$5.39 billionN/A-31.08Insider Selling
Gap Up
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.8$81.49-3.1%$5.20 billionN/A-6.64
AVIR
Atea Pharmaceuticals
1.7$60.89-1.5%$4.96 billionN/A0.00Upcoming Earnings
Decrease in Short Interest
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$87.20-5.9%$4.92 billion$1.11 billion28.04
Schrödinger logo
SDGR
Schrödinger
1.7$65.07-6.9%$4.83 billion$85.54 million0.00Earnings Announcement
Insider Selling
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.2$76.30-0.9%$4.49 billion$6.87 million-7.37Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.3$72.78-1.1%$4.44 billion$806.43 million-10.31Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.18-4.1%$4.42 billion$204.89 million-36.48
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$121.52-4.4%$4.33 billion$26.52 million-10.71Earnings Announcement
Analyst Revision
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.1$59.58-0.9%$4.23 billion$306.98 million-8.52
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.3$21.39-4.3%$4.06 billion$114.62 million-8.62Analyst Revision
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$56.47-1.4%$3.98 billion$36.13 million-84.28Analyst Report
Decrease in Short Interest
Analyst Revision
Insmed logo
INSM
Insmed
1.2$38.77-1.7%$3.93 billion$136.47 million-14.91Analyst Report
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$47.22-3.4%$3.92 billionN/A-6.36
IMAB
I-Mab
1.3$49.99-1.4%$3.55 billion$4.31 million-1.73
Arvinas logo
ARVN
Arvinas
1.9$70.69-1.9%$3.52 billion$42.98 million-27.61
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.5$47.83-2.2%$3.40 billion$117.91 million-9.70Analyst Report
FibroGen logo
FGEN
FibroGen
1.6$33.62-6.1%$3.27 billion$256.58 million-12.88Analyst Report
Analyst Revision
Gap Up
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$117.99-2.3%$3.26 billionN/A-58.70Analyst Report
Analyst Revision
Gap Up
LEGN
Legend Biotech
1.2$25.48-3.8%$3.24 billion$64.39 million0.00Increase in Short Interest
News Coverage
MorphoSys logo
MOR
MorphoSys
0.4$24.14-0.2%$3.18 billion$80.43 million114.96
Alkermes logo
ALKS
Alkermes
1.2$19.40-0.6%$3.07 billion$1.17 billion-42.17
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$70.50-1.8%$3.04 billion$421.03 million24.82Analyst Report
Viela Bio logo
VIE
Viela Bio
0.8$52.99-0.1%$2.91 billion$50 million-7.55
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.8$49.50-5.9%$2.90 billionN/A-27.20Analyst Report
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.6$23.95-2.5%$2.88 billion$306.49 million26.91
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.05-0.7%$2.85 billion$644.77 million-10.71Increase in Short Interest
OPKO Health logo
OPK
OPKO Health
1.9$4.42-4.5%$2.83 billion$901.90 million-24.55Insider Buying
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$33.58-3.2%$2.81 billion$60,000.00-10.43
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$10.42-0.6%$2.77 billion$182.24 million-9.06Analyst Report
Xencor logo
XNCR
Xencor
1.0$43.43-3.4%$2.60 billion$156.70 million-31.02
ALX Oncology logo
ALXO
ALX Oncology
2.1$72.41-5.2%$2.55 billionN/A0.00Upcoming Earnings
Decrease in Short Interest
Gap Down
PRLD
Prelude Therapeutics
1.0$54.44-4.3%$2.48 billionN/A0.00Upcoming Earnings
Gap Down
This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.